← Back to Search

Cholinergic Agonist and Alpha-2 Adrenergic Agonist

Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally for Eye Diseases

Phase 2
Waitlist Available
Research Sponsored by LENZ Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour
Awards & highlights

Study Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Eligible Conditions
  • Eye Diseases
  • Refractive Errors
  • Presbyopia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Subjects With at Least a 3-line Improvement in Near Visual Acuity in the Study Eye

Trial Design

3Treatment groups
Experimental Treatment
Group I: Vehicle Ophthalmic Solution dosed bilaterallyExperimental Treatment3 Interventions
Proprietary Vehicle ophthalmic solution
Group II: Combination ophthalmic solution (LNZ101) dosed bilaterallyExperimental Treatment3 Interventions
Aceclidine/Brimonidine combination ophthalmic solution
Group III: Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterallyExperimental Treatment3 Interventions
Aceclidine ophthalmic solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aceclidine ophthalmic solution
2022
Completed Phase 2
~120
Aceclidine+Brimonidine combination ophthalmic solution
2023
Completed Phase 3
~710
Vehicle Proprietary Ophthalmic Solution
2022
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,974 Total Patients Enrolled
14 Trials studying Eye Diseases
2,920 Patients Enrolled for Eye Diseases
LENZ Therapeutics, IncLead Sponsor
8 Previous Clinical Trials
1,488 Total Patients Enrolled
5 Trials studying Eye Diseases
1,389 Patients Enrolled for Eye Diseases
Alisyn FacemireStudy DirectorLENZ Therapeutics, Inc

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
2022. "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05294328.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top